Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1126
Shown on this page
10
Current sort
Recently updated
Campus scope
Northwestern Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Northwestern Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1117–1126 of 1,126 matching trials with a site at Northwestern Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

NCT03911973
Site status not listed — check the official record
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
Gedatolisib, Talazoparib
Drug
Lead sponsor
Kari Wisinski
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Nov 9, 2026, 3:37 PM EST
Active, not recruiting Not applicable Interventional

EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

NCT03042104
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Diseases, Aortic Stenosis, Severe
Interventions
Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
74
States / cities
Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Nov 9, 2026, 3:37 PM EST
Recruiting Not applicable Interventional

PARTNER 3 Trial - Aortic Valve-in-Valve

NCT03003299
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Stenosis, Aortic Stenosis, Severe
Interventions
Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2038
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Nov 9, 2026, 3:37 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

NCT04809376
Site status not listed — check the official record
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly
Drug
Lead sponsor
Paradigm Biopharmaceuticals USA (INC)
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Nov 9, 2026, 3:37 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053
Status at this site: Recruiting
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
35,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2062
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 9, 2026, 3:37 PM EST
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
Site status not listed — check the official record
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Nov 9, 2026, 3:37 PM EST
Recruiting Phase 3 Interventional Accepts healthy volunteers

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

NCT05620784
Status at this site: Recruiting
View directory record Official record
Conditions
BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions
Furosemide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 9, 2026, 3:37 PM EST
Active, not recruiting Phase 3 Interventional Results available

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990
Site status not listed — check the official record
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
72
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 9, 2026, 3:37 PM EST
Recruiting Phase 2 Interventional

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

NCT05733000
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride, Hydroxychloroquine, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Nov 9, 2026, 3:37 PM EST
Active, not recruiting Phase 2 Interventional

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

NCT03071874
Site status not listed — check the official record
View directory record Official record
Conditions
Meningioma
Interventions
AZD2014
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Nov 9, 2026, 3:37 PM EST

About this Northwestern Medicine institution page

What this page lists
ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Northwestern University at any site, browse by condition, or browse by U.S. city.